Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-na ïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Condition: Leukemia Interventions: Drug: Pirtobrutinib; Drug: Obinutuzumab; Drug: Venetoclax; Drug: Valacyclovir; Drug: Allopurinol Sponsors: M.D. Anderson Cancer Center; Loxo Oncology, Inc.; The Leukemia and Lymphoma Society Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allopurinol | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Research | Valtrex